Company News: Curetis Reports Results of the Annual General Meeting Held on June 21, 2018
– All proposed AGM resolutions approved by shareholders
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual General Meeting (“AGM”) held in Amsterdam on June 21, 2018.
The Company’s shareholders approved all items on the agenda of the AGM. Oliver Schacht, Ph. D., and Dr. Achim Plum have been re-appointed as Managing Directors for a three-year term until December 31, 2021, respectively. Further, Christopher Bernard, President & CEO of Curetis USA, Inc. and EVP Global Sales has been appointed as a member of the Company’s Management Board for a three-year term until the end of AGM 2021.
In addition to these Management Board appointments, Dr. Rudy Dekeyser was re-elected to the Company’s Supervisory Board for another one-year term and Dr. Werner Schaefer was re-elected for another two-year term. Moreover, the Supervisory Board has been authorized to grant stock options to Managing Directors. Further, the proposed extension of the designation of the Management Board to limit or exclude pre-emptive rights on newly issued shares or rights to subscribe for shares, and an extension of authorization of the Management Board to repurchase shares as well as to issue new shares or grant rights to subscribe for shares in relation to strategic capital raising(s) were also approved by the shareholders.
“The appointment of Chris Bernard in his role as CEO of our U.S. organization to the Management Board of Curetis N.V. reflects the great relevance that the U.S. market has gained for us following the clearance of the Unyvero System and the Unyvero LRT Application Cartridge by the U.S. FDA,” said Oliver Schacht, CEO of Curetis. “Moreover, we are pleased that all proposed AGM resolutions have been approved by our shareholders giving the Management Board and the Supervisory Board the flexibility to further drive the strategic and commercial development of the Company. Last but not least, I personally and on behalf of Dr. Plum would like to thank the shareholders for their trust and our re-appointments as Managing Directors.”
The Curetis N.V. 2018 AGM meeting minutes, detailed voting results as well as further information are reported on Curetis’ website at: http://www.curetis.com/en/investors/share-information/annual-general-meeting.html